Sign in
Stories
FDA Approval Boosts Kamada's Expansion
Share
FDA Approval Boosts Kamada's Growth
FDA Approval for Kamada's Cytogam Produc...
Immunoglobulin Market Growth and Innovat...
ANJESO Drug Insight and Market Forecast
Advancements in Cancer Treatment and Mar...
Biosimilar Interleukins Market Growth
Overview
API
Kamada secures US FDA approval to manufacture Cytogam in Israel, concluding a successful technology transfer from CSL Behring. The approval enhances plant efficiency, with expectations of expanding their FDA-approved IgG product line.
Ask a question
Considering the rising demand for advanced genetic disorder treatments, how might healthcare policies evolve to support access to such therapies?
How might the FDA approval impact Kamada's market positioning and competitiveness in the pharmaceutical industry?
What strategies could Kamada implement to capitalize on the projected growth in the global plasma derived therapy market?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage
biosp
pharm
prece
proth